When *EBioMedicine* first launched in late 2014, the world watched in horror as an Ebola virus outbreak claimed the lives of thousands of West Africans. The outbreak spurred a massive response by researchers around the world to develop effective therapeutics and a protective vaccine. As we embark upon our third full year here at the journal, we can now indeed celebrate the success of an Ebola vaccine which appears to be completely protective in humans. In a trial published in December 2016 in *The Lancet*, this recombinant respiratory syncytial virus (rRSV)-based vaccine was administered to more than 5800 people in Guinea, all of whom were protected from disease. We praise the large-scale collaborative effort of both clinical and basic science researchers which has brought us closer to preventing further Ebola outbreaks. Moving forward in 2017, we hope a similar mobilization of efforts will lead us towards better diagnostic and therapeutic options for patients affected by Zika virus. Although quite different from Ebola virus in its clinical presentation, this emergent and wide-spread public health threat will require the same degree of scientific collaboration across basic and clinical disciplines.

2016 saw many exciting translational advances---in addition to the success with Ebola vaccine development, results early in 2016 showed that a modified version of the widely publicized RV144 HIV vaccine protocol was safe and well tolerated. While the RV144 vaccine protocol itself was 31% protective, the new immunization protocol hopes to increase efficacy in part by using an improved adjuvant, and including an additional booster shot at the one year mark. This early success with the modified protocol has given the green light for one of the largest scale HIV vaccine trials to date---HVTN 702---a phase IIb/III clinical trial which has just began enrolling patients in South Africa. While it will be some time before we hear results, our fingers are tightly crossed that we will see the dial move even further upward for efficacy in preventing new HIV infections.

New advances with checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell based therapies have of course dominated many cancer therapy-based headlines over the past year. In 2017 we expect many more great ideas to develop further within this explosive area of therapeutic research---such as defining new cancer antigens to target, improving safety, and exploring combination therapies. 2016 also saw other exciting news in cancer research, with the first US FDA approval for liquid biopsies---in this case, for the detection of non-small cell lung carcinoma. These tests look at sequences of DNA fragments from lysed cancer cells that are present in the blood of affected patients. If specific cancer-associated gene mutations are found, this information can help clinicians make better, tailor-made, treatment decisions. Because these tests are non-invasive, clinicians also hope to be able to use liquid biopsies for early detection of specific cancers. Liquid biopsies may still not be as accurate in tracking as broad a spectrum of tumor mutations as traditional tissue biopsy, but we expect this simple blood test has the potential to greatly change our ability to rapidly and affordably diagnose and treat cancers. We also look forward to seeing this field progress further in the coming year.

Rapid advancements over the past year in bioengineering are bringing science fiction-like therapies closer to the reality of our clinics and doctors' offices. Three-dimensional bioprinting is now at the stage where we can create arteries, liver tissue, bone and renal tubes that mimic the functional properties their biological counterparts. These live tissues can be used to test drugs and model diseases, and a long-term hope is that the technology will evolve to produce entire artificial human organs, eliminating the need for human-to-human transplants. While we are unlikely to see bioprinted organs ready for human transplantation in 2017, we imagine the year ahead will bring more exciting news in 3D reconstruction of human tissue. The clinical use of artificial blood is also closer to becoming a reality. In data presented late last year, researchers have now shown that artificial "cells" composed of nanoparticles are able to respond to blood pH to capture oxygen in the lungs, and release it in the tissues like authentic red blood cells---preventing blood-loss shock in preclinical models. Furthermore, these nanoparticles can be dehydrated for easy storage, and then reconstituted on-the-go. This biomaterial also likely has some way to go before we can use it to save human lives, but we are hopeful we may soon see artificial red blood cell replacement as a much-needed viable therapeutic option---such as in field-based operations where transport and storage of sufficient blood stores may not be possible. We can also celebrate the recent FDA approval in 2016 of the first artificial pancreas, which is an electronic device that can be worn outside the body by type 1 diabetes (T1D) patients. This life-saving advance both monitors glucose levels and administers insulin as needed in response to those levels, eliminating the need for around-the-clock monitoring by T1D patients and their families. We are thrilled to see how rapidly technology is advancing these and other engineered treatment options, and look forward to seeing solid translational studies in biomaterials and bioengineering in our journal moving forward into 2017.

In addition to these quickly moving fields of infectious disease, immunotherapy, cancer, and bioengineering as highlighted above---we also expect to see rapid developments in the fields of microbiome research, neurology and neuroscience, aging, and metabolism---among others. Given our hope to serve as a centralized home for solid translational research from both basic and clinical ends of the biomedical spectrum---expect to see us actively engaging the field at conferences in these areas, asking you about your work, and how we can help translate science to improve human health.
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